A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins

Cancer Research

Volumn 70, Issue 7, 2010, Pages 2604-2612

  Quaglino, Elena ^a   Mastini, Cristina ^a   Amici, Augusto ^b   Marchini, Cristina ^b   lezzi, Manuela ^c   Lanzardo, Stefania ^a   De Giovanni, Carla ^d   Montani, Maura ^b   Lollini, Pier Luigi ^d   Masucci, Giuseppe ^e   Fornl, Guido ^a   Cavallo, Federica ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CHIMERIC PROTEIN; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNIZATION; CELL MEMBRANE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ELECTROPORATION; FEMALE; GENETIC CODE; GENETIC TRANSFECTION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN DOMAIN; TRANSGENIC MOUSE; TUMOR IMMUNITY; WILD TYPE;

EID: 77950801051     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2548     Document Type: Article

References (39)

1. Lllini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006;6:204-216
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182
3. 3. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712 (Pubitemid 19147683)
4. Lindencrona JA, Preiss S, Kammertoens T, et al. CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004;109:259-264
5. Reilly RT, Machieis JP, Emens LA, et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 2001;61:880-883
6. 6. Quaglino E, Rolla S, lezzi M, et al. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest 2004;113:709-717 (Pubitemid 38544164)
7. Park JM, Terabe M, Sakai Y, et al. Early role of CD4+ TM cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005;174:4228-4236
8. 8. Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A 1998;95:652-656 (Pubitemid 28083798)
9. 9. Cavallo F, Calogero RA, Forni G. Are oncoantigens suitable targets for anti-tumour therapy?. Nat Rev Cancer 2007;7:707-713 (Pubitemid 47327413)
10. Ercolini AM, Ladle BH, Manning EA, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med 2005;201:1591-1602
11. 11. Rolla S, Nicolo C, Malinarich S, et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 2006;177:7626-7633 (Pubitemid 44846277)
12. Ambrosino E, Spadaro M, lezzi M, et al. Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res 2006:66:7734-7740
13. Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, et al. Self-antigen-specific CDS+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 2009;206:849-866
14. 14. Engelhorn ME, Guevara-Patino JA, Noffz G, et al. Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med 2006;12:198-206. (Pubitemid 43214746)
15. Fattori E, Aurisicchio L, Zampaglione I, et al. ErbB2 genetic cancer vaccine in nonhuman primates: relevance of single nucleotide polymorphisms. Hum Gene Ther 2008;20:253-265
16. Luo W, Hsu JC, Kieber-Emmons T, Wang X, Ferrone S. Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases. Cancer Chemother Biol Response Modif 2005;22:769-787
17. 17. Zhang X, Smith DS, Guth A, Wysocki LJ. A receptor presentation hypothesis for T cell help that recruits autoreactive B cells. J Immunol 2001;166:1562-1571 (Pubitemid 32114636)
18. 18. Sobel ES, Kakkanaiah VN, Kakkanaiah M, Cheek RL, Cohen PL, Eisenberg RA. T-B collaboration for autoantibody production in lpr mice is cognate and MHC-restricted. J Immunol 1994;152:6011-6016 (Pubitemid 24174184)
19. Jensen PE, Kapp JA. Bystander help in primary immune responses in vivo. J Exp Med 1986;164:841-854
20. 20. Smith CM, Wilson NS, Waithman J, et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 2004;5:1143-1148 (Pubitemid 39549628)
21. 21. Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998;188:1553-1561 (Pubitemid 28516100)
22. Kianizad K, Marshall LA, Grinshtein N, et al. Elevated frequencies of self-reactive CDS+ T cells following immunization with a xenoantigen are due to the presence of a heteroclitic CD4+ T-cell helper epitope. Cancer Res 2007;67:6459-6467
23. Rovero S, Amici A, Carlo ED, et al. DNA vaccination against rat her-2/ Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000;165: 5133-5142
24. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIHβT3 cells. Science 1987;237:178-182
25. 25. Jacob J, Radkevich O, Fomi G, et al. Activity of DNA vaccines en-coding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 2006;240:96-106. (Pubitemid 44353445)
26. 26. Rovero S, Boggio K, Carlo ED, et al. Insertion of the DNA for the 163-171 peptide of IL1 ß enables a DNA vaccine encoding p185 (neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice. Gene Ther 2001 ;8:447-452 (Pubitemid 32266400)
27. 27. Rolla S, Marchini C, Malinarich S, et al. Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain. Hum Gene Ther 2008;19:229-240 (Pubitemid 351442724)
28. Boggio K, Nicoletti G, Di Carlo E, et al. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 1998;188:589-596
29. Piechocki MP, Ho YS, Pilon S, Wei WZ. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 2003;171:5787-5794
30. Quaglino E, lezzi M, Mastini C, et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004;64:2858-2864
31. Mastini C, Becker PD, lezzi M, et al. Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her2/neu transgenic mice. Curr Cancer Drug Targets 2008;8:230-242
32. 32. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2pertuzumab complex. Cancer Cell 2004;5:317-328 (Pubitemid 38482068)
33. 33. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-760 (Pubitemid 36227628)
34. Nanni P, Pupa SM, Nicoletti G, et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 2000;87: 186-194
35. 35. Curcio C, Di Carlo E, Clynes R, et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003;111:1161-1170 (Pubitemid 36519933)
36. Wei WZ, Shi WP, GaIy A, et al. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 1999;81:748-754
37. Hayakawa Y, Rovero S, Forni G, Smyth MJ. α-Galactosylceramide (KRN7000) suppression of chemical- and oncogene-dependent carcinogenesis. Proc Natl Acad Sci U S A 2003;100:9464-9469
38. 38. Finkle D, Quan ZR, Asghari V, et al. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 2004;10:2499-2511 (Pubitemid 38445712)
39. 39. Cavallo F, Offringa R, van der Burg SH, Fomi G, Melief CJ. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006;90:175-213. (Pubitemid 43765801)